In 2019, ROP affected 27,000 premature neonates in the US and is a leading cause of childhood blindness. Laser photocoagulation and anti-VEGF [vascular endothelial growth factor] therapy - the two ...

The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be ...

In 2011, the BEAT-ROP study was published in the New England Journal of Medicine. That study revealed that agents called anti-vascular endothelial growth factor (anti-VEGF) agents may also be ...

Progress in oncology, and more recently ophthalmology, led to the development of VEGF antagonists, three of which are now approved for the treatment of wet AMD. Recent discoveries in ophthalmology ...

Today, angiogenesis is the central focus in the pathogenesis of this disease, with VEGF identified as a major mediator of this process. These advances have opened the door for targeted anti-VEGF ...

Anti-VEGF injections are commonly used to treat macular ... such as retinopathy of prematurity (ROP), to their later years, including diabetic macular edema (DME), diabetic retinopathy (DR ...